Chimeric: Media Thread, page-832

Just re-watched the 2023 presentation from Dr Maiti from MD Anderson clinic in the US re Advent NK MLA trial

a few points to note:

- MD Anderson is the premier cancer clinic in the US

- Responsible for 9/10 latest FDA approvals for AML

- A successful trial with CHM NK allogenic cells will be practise changing

- targeting 1 st line therapy (in combination with existing standard of care)

- Rebecca alluded to early efficacy signals in the 1st cohort during her presentation at TechKnow.

- Rebecca also advised that trial is powering along

- MD Anderson gets 40 AML patients a month so enrolling patients won’t be difficult

- Dr Māiti provides strong rationale for why he pursued a collaboration with CHM
- Dr Maiti says a successful phase 1 , would likely result in a breakthrough designation from the FFA